Honing Biosciences, spin-off from Institut Curie created in 2018, develops technologies to regulate protein transport in drug-cells in order to optimize their efficacy and reduce their potential toxicity.
Honing Biosciences, spin-off from Institut Curie, secures €2 million in financing from Elaia, a private investor and BPI France. The funds will accelerate the development of the company’s proprietary cell therapy technology and initiate new areas of development. The funding will also help strengthen the team for the development of pre-clinical models.
2020.07.07 / 2min read.